Axsome Therapeutics

Axsome has had a tremendous start to 2026, including robust year-over-year growth for our commercial business, a recent FDA drug approval, and continued expansion and advancement of our industry-leading development pipeline. Learn more here: axsometherapeuticsinc.gcs-web.com/news-releases/…

Today we initiated the CLARITY Phase 3 trial in adults with major depressive disorder with excessive daytime sleepiness symptoms as we continue to advance our innovative CNS pipeline. Learn more here: bit.ly/3OqsIw3

Today we reported 4Q and full-year 2025 financial results highlighting the strong growth of our commercial products and advancement across our expanding CNS pipeline. Learn more here: bit.ly/4tR6qDO

We’re pleased to announce that the first patient has been dosed in the FORWARD Phase 3 trial of AXS-14 for the management of fibromyalgia, a chronic neurological pain condition where treatment options remain limited. Learn more here: bit.ly/3NLabKe #fibromyalgia

Our third quarter results highlight our continued commercial performance and execution across our innovative late-stage pipeline. Read more about our progress in today’s news release: bit.ly/4nUP2Kl

Axsome Therapeutics has the honor of ringing today’s @NasdaqExchange Opening Bell in connection with its Frontiers in Brain Health R&D Day event being held today. Learn more here: bit.ly/4kTPKWC #Nasdaq #OpeningBell

We’re reporting earnings for the second quarter of 2025 on August 4, including a call with management to discuss these results and provide a business update. Learn more here: bit.ly/461mkSE

Join us at our Frontiers in Brain Health R&D Day for a look into our innovative CNS pipeline. Hear from physician thought leaders and the Axsome team discussing our current indications and clinical programs in #neurology and #psychiatry. Learn more here: bit.ly/45WNH0b

During Alzheimer’s & Brain Awareness Month, we are encouraging people to prioritize brain health and share resources that could help people affected by Alzheimer’s disease and other CNS disorders. Learn more here: bit.ly/4k2Nqfv #AlzheimersAwareness

Come and meet with our team at this year’s American Headache Society (@AHSheadache) Annual Meeting in Minneapolis where we’re sharing data from across our #migraine clinical program. Learn more about our presentations here: bit.ly/4n82TNW #AHSAM #AHS25

In honor of June’s Migraine and Headache Awareness Month theme, “Your Path to Better Days,” Axsome is sharing resources for patients and their loved ones affected by migraine. Learn more about here: bit.ly/45qlkqU #MigraineAwareness #Migraine #MHAM2025

We look forward to connecting with the sleep community this week at the APSS #SLEEP2025 conference in Seattle, where we will share data from our innovative research programs in narcolepsy and obstructive sleep apnea (OSA). Learn more here: bit.ly/43DWOkJ

SYMBRAVO® (meloxicam and rizatriptan) is now available in the United States. Please see full Prescribing Information, including Boxed Warning, and the Medication Guide. Learn more here: bit.ly/4kWrbse

We’re presenting at @ASCPorg's Annual Meeting in Scottsdale this week. Please join us at our posters to meet the team and hear more about the presentations. Learn more here: bit.ly/4jrkuxr #ASCP2025

We are proud to join @MentalHealthAm (MHA) and the broader mental health advocacy community to raise awareness and promote action during this year’s Mental Health Month. Learn more about how Axsome is taking action and find additional resources here: bit.ly/3GysDCi #MHAM

Please join us at the 2025 AAN Annual Meeting where we have multiple presentations including pivotal Phase 3 results of the ACCORD-2 and SYMPHONY trials and a network meta-analysis of AXS-07 vs oral CGRPs. Learn more here: bit.ly/4iV4yUv #AAN2025 #AANAM

Today, we announced that the FOCUS Phase 3 trial of solriamfetol in adults with ADHD achieved its primary and key secondary endpoints. Learn more here: bit.ly/4iGgBoN #ADHD

The primary endpoint was achieved in the EMERGE Phase 3 trial in migraine patients experiencing inadequate response to oral CGRP inhibitors. Read here to learn more: bit.ly/3QwSsog

Thank you, @bradloncar and @BiotechTVHQ for joining us at One World Trade today to discuss our 2024 accomplishments and our 2025 plans to advance our mission to deliver scientific breakthroughs patients living with serious CNS conditions:

Today we announced positive results from the ENCORE long-term Phase 3 trial of AXS-12 in narcolepsy. Please read the full release for more details: bit.ly/3Z5kSJU #narcolepsy